KAIROS PHARMA LTD (KAPA) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:KAPA • US48301N1046

0.6613 USD
-0.01 (-0.93%)
Last: Feb 3, 2026, 01:14 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KAPA. KAPA was compared to 524 industry peers in the Biotechnology industry. KAPA has a great financial health rating, but its profitability evaluates not so good. KAPA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • KAPA had negative earnings in the past year.
  • KAPA had a negative operating cash flow in the past year.
KAPA Yearly Net Income VS EBIT VS OCF VS FCFKAPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -1M -2M -3M

1.2 Ratios

  • KAPA's Return On Assets of -62.76% is in line compared to the rest of the industry. KAPA outperforms 41.03% of its industry peers.
  • KAPA has a Return On Equity (-66.05%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.76%
ROE -66.05%
ROIC N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KAPA Yearly ROA, ROE, ROICKAPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KAPA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KAPA Yearly Profit, Operating, Gross MarginsKAPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for KAPA has been increased compared to 1 year ago.
  • There is no outstanding debt for KAPA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KAPA Yearly Shares OutstandingKAPA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
KAPA Yearly Total Debt VS Total AssetsKAPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • An Altman-Z score of 17.20 indicates that KAPA is not in any danger for bankruptcy at the moment.
  • KAPA has a better Altman-Z score (17.20) than 87.79% of its industry peers.
  • There is no outstanding debt for KAPA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.2
ROIC/WACCN/A
WACCN/A
KAPA Yearly LT Debt VS Equity VS FCFKAPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • A Current Ratio of 16.56 indicates that KAPA has no problem at all paying its short term obligations.
  • KAPA has a Current ratio of 16.56. This is amongst the best in the industry. KAPA outperforms 93.32% of its industry peers.
  • A Quick Ratio of 16.56 indicates that KAPA has no problem at all paying its short term obligations.
  • KAPA's Quick ratio of 16.56 is amongst the best of the industry. KAPA outperforms 93.32% of its industry peers.
Industry RankSector Rank
Current Ratio 16.56
Quick Ratio 16.56
KAPA Yearly Current Assets VS Current LiabilitesKAPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

  • The earnings per share for KAPA have decreased strongly by -33.55% in the last year.
EPS 1Y (TTM)-33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • KAPA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.70% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.67%
EPS Next 2Y-28.45%
EPS Next 3Y-31.68%
EPS Next 5Y-13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KAPA Yearly Revenue VS EstimatesKAPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 200M 400M 600M 800M
KAPA Yearly EPS VS EstimatesKAPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KAPA. In the last year negative earnings were reported.
  • Also next year KAPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KAPA Price Earnings VS Forward Price EarningsKAPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KAPA Per share dataKAPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

  • A cheap valuation may be justified as KAPA's earnings are expected to decrease with -31.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.45%
EPS Next 3Y-31.68%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for KAPA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KAIROS PHARMA LTD

NYSEARCA:KAPA (2/3/2026, 1:14:17 PM)

0.6613

-0.01 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners2.14%
Inst Owner Change-6.62%
Ins Owners35.36%
Ins Owner Change0%
Market Cap13.77M
Revenue(TTM)N/A
Net Income(TTM)-5.06M
Analysts82.22
Price Target8.5 (1185.35%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.77%
Min EPS beat(2)-42.6%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-56.62%
Min EPS beat(4)-124.09%
Max EPS beat(4)-2.94%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.8
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.37
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.76%
ROE -66.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.56
Quick Ratio 16.56
Altman-Z 17.2
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y-31.67%
EPS Next 2Y-28.45%
EPS Next 3Y-31.68%
EPS Next 5Y-13.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-175.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-677.2%
EBIT Next 3Y-180.07%
EBIT Next 5Y-129.35%
FCF growth 1Y-4982.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4982.72%
OCF growth 3YN/A
OCF growth 5YN/A

KAIROS PHARMA LTD / KAPA FAQ

What is the ChartMill fundamental rating of KAIROS PHARMA LTD (KAPA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KAPA.


What is the valuation status of KAIROS PHARMA LTD (KAPA) stock?

ChartMill assigns a valuation rating of 0 / 10 to KAIROS PHARMA LTD (KAPA). This can be considered as Overvalued.


How profitable is KAIROS PHARMA LTD (KAPA) stock?

KAIROS PHARMA LTD (KAPA) has a profitability rating of 1 / 10.


Can you provide the financial health for KAPA stock?

The financial health rating of KAIROS PHARMA LTD (KAPA) is 8 / 10.